Epidemiological Aspects of Osteosarcoma, Giant Cell Tumor and Chondrosarcoma Musculoskeletal Tumors - Experience of the National Rehabilitation Institute, Mexico City

  • DelaGarza-Montano, P (Department of Neuroscience, National Rehabilitation Institute) ;
  • Estrada-Villasenor, E (Pathology Service, National Rehabilitation Institute) ;
  • Dominguez Rubio, R (Health Sciences, National Rehabilitation Institute) ;
  • Martinez-Lopez, V (Unit of Tissue Engineering, Cell Therapy and Regenerative Medicine, National Rehabilitation Institute) ;
  • Avila-Luna, A (Department of Neuroscience, National Rehabilitation Institute) ;
  • Alfaro-Rodriguez, A (Department of Neuroscience, National Rehabilitation Institute) ;
  • Garciadiego-Cazares, D (Unit of Tissue Engineering, Cell Therapy and Regenerative Medicine, National Rehabilitation Institute) ;
  • Carlos, A (Electron Microscopy Laboratory, National Rehabilitation Institute) ;
  • Hernandez-Perez, AD (Electron Microscopy Laboratory, National Rehabilitation Institute) ;
  • Bandala, C (Health Sciences, National Rehabilitation Institute)
  • Published : 2015.10.06


Background: Primary bone neoplasms are rare, contributing only 0.2% of the global burden of all human malignancies. Osteosarcoma (OS) and chondrosarcoma (CS) are the most common malignancies of bone. The giant cell tumor of bone (GCTb) is a benign tumor with behavior characterized by osteolytic bone destruction. The OS, CS and GCTb affect both sexes, all races and generally have incidence peaks regarding the age of the patient which vary according to the tumor type. We analyzed the incidences of OS, CS and GCTb and their relations with gender and age in patients treated in the National Rehabilitation Institute (INR, for its acronym in Spanish) over a period of nine years. Materials and Methods: In the study period, clinic pathological data for 384 patients were obtained with clinical, radiological and histopathological diagnosis for OS, GCTb and CS. Data analysis was performed using the chi-square and Fisher's exact tests. Results: From 2006 to 2014 were recorded 384 cases of bone malignancies in the database of INR. The GCTb had the highest incidence (53.1%), followed by OS (31.3%) and finally the CS (15.6%). The overall average age was $33.6{\pm}15.8$ years and the overall frequency of gender had a ratio of 1/1.03 male/female. The states with the highest incidence were Distrito Federal and Estado de Mexico with 29.2% and 25.3% respectively. Malignant neoplasms of bone assessed in the course of nine years show three significant increases in 2008, 2011 and 2014 (p=0.14). We found association between sex and tumor type (p=0.03), GCTb and CS predominated in females (54.9% and 56.6% respectively), while for the OS males were most affected (59.1%). Age was different in relation with tumor type (p=0.0001), average age was $24.3{\pm}11.2$ years for OS, $34.5{\pm}13$ years for GCTb and $49.2{\pm}18.5$ years for CS. Furthermore, associations of tumor type with topographic location of the primary tumor (P=0.0001) were found. Conclusions: In this study we can see that incidence of musculoskeletal tumor in our population is continuously increasing and in nine years an approximately 200% increase of musculoskeletal tumor cases was observed.


Osteosarcoma;chondrosarcoma;giant cell tumor of bone;Mexico


  1. Baena Ocampo LC, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R (2009). Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diag Path, 13, 16-21.
  2. Choeyprasert W, Pakakasama S, Sirachainan N, et al (2014). Comparative outcome of thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. Asian Pac J Cancer Prev, 15, 9823-89.
  3. De la Garza NJM, Ceccopieri CA, Cruz Ortiz H, Diaz Rodriguez LR, Martinez Macias R (1999). Tumor de celulas gigantes de hueso. Aspectos generales de 11 casos. Rev Med Hosp Gen Mex, 62, 240-4.
  4. Fletcher C, Krishnan Unni KK, Mertens F (2002). editors: WHO classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 11: 298.
  5. Giuffrida AY, Burgueno JE, Koniaris LG, et al (2009). Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am, 91, 1063-72.
  6. Gomez-Martinez R, Silva-Padilla N, Gutierrez-de la OM, Tavares-Macias G (2012). Osteosarcoma metastasico al diagnostico: caracteristicas clinicas y pronostico. GAMO, 11, 296-9.
  7. Hasan ZA, Zaragoza JL, Jimenez-Villanueva X, et al (2001). Condrosarcoma pelvico secundario y enfermedad de Ollier. Informe de un caso. Rev Mex Ortop Traum, 15, 303-6.
  8. Jiang N, Qin CH, Tan CX, et al (2013). A retrospective analysis of 140 patients with giant cell tumor in the extremity: a multicenter study based on four hospitals in South China. Cancer Epidemiol, 37, 294-9.
  9. Kim SS, Park YK (2014). Significance of MTA1 in the molecular characterization of osteosarcoma. Cancer Metastasis Rev, 33, 981-91.
  10. Mirabello L, Troisi RJ, Savage SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 115, 1531-43.
  11. Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages, and elderly persons. Int J Cancer, 125, 229-34.
  12. Muscolo DL, Farfalli G, Aponte-Tinao LA, Ayersa MA (2009). Actualizacion en osteosarcoma. Rev Asoc Argent Ortop Traumatol, 74, 85-101.
  13. Niu X, Zhang Q, Hao L, et al (2012). Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am, 94, 461-7.
  14. Palomo-Colli MA, Pena-del Castillo H, Juarez Villegas LE, et al (2012). Resultados del tratamiento de ninos con osteosarcoma en el hospital infantil de mexico federico gomez. GAMO, 11, 306-13.
  15. Pring ME, Weber KL, Unni KK, Sim FH (2001). Chondrosarcoma of the pelvis: a review of sixty-four cases. J Bone Joint Surg Am, 83, 1630-42.
  16. Rizo-Rios P, Sierra-Colindres MI, Vazquez Pinon G, et al (2007). Registro hospitalario de cancer: compendio de cancer 2000-2004. Revincan, 2, 203-87.
  17. Sanchez Torres LJ, Flores Flores A, Santos Hernandez M (2012). Tumor oseo de celulas gigantes en pacientes de menos de 20 anos. Rev Mex Ortop Ped, 14, 26-30.
  18. Sung HW, Kuo DP, Shu WP, et al (1982). Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am, 64, 755-61.
  19. Turcotte RE (2006). Giant cell tumor of bone. Orthop Clin NorthAm, 37, 35-51.
  20. Van Der Geest IC, Servaes P, Schreuder HW, et al (2002). Chondrosarcoma of bone: functional outcome and quality of life. J Surg Oncol, 81, 70-4.
  21. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014). Childhood and adolescent cancer statistics. Cancer J Clin, 64, 83-103.
  22. Wiromrat P, Jetsrisuparb A, Komvilaisak P, et al (2012). Incidence and survival rates among pediatric osteogenic sarcoma cases in Khon Kaen, Thailand, 1985-2010. Asian Pac J Cancer Prev, 13, 4281-4.
  23. Yang ZM, Tao HM, Ye ZM, Li WX, Lin N, Yang DS (2012). Multivariate analysis of the prognosis of 37 chondrosarcoma patients. Asian Pac J Cancer Prev, 13, 1171-6.

Cited by

  1. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone vol.14, pp.1, 2016,